Background: Serum leptin level and bone mineral density (BMD) are widely assumed to be positively associated with body fat mass. Numerous attempts have been made to document the relationship between leptin and BMD, but the results are inconsistent, especially in diabetic patients.
Introduction
It has generally been accepted that body fat mass is one of the strongest predictors of bone mineral density (BMD) 1) , but the precise mechanism which explains this relationship remains unclear. The previous studies have shown that increased aromatization of androgen to estrogen 2) , decreased sex-hormone binding globulin 3) , augmentation of bone formation by high circulating levels of insulin 4) , mechanical effects of increased weight bearing 5) , and leptin 6) could affect BMD in obese patients.
Leptin is an adipocyte-derived hormone produced by the ob gene 7) and binds to its receptor in the hypothalamus, where the hormone acts to decrease fat mass through suppressing appetite with a reduction in food intake and enhancing energy consumption by a feedback mechanism 8) . This mechanism explains a positive correlation between plasma leptin level and body fat mass 9) . In addition to its adipostatic function, recent evidence suggests that leptin directly stimulates osteoblastic differentiation. In a previous experiment using immortalized human marrow stromal cell lines, human recombinant leptin stimulated differentiation of stromal cells to osteoblasts while inhibiting their differentiation to adipocytes 10) .
Administration of leptin to leptin deficient ob/ob knockout mice caused an increase in the number of osteoblasts at the endocortical surface 11) . Previous studies have demonstrated that leptin has a positive effect on bone metabolism by enhancing osteoblast formation and inhibiting osteoclast generation 12) . Leptin given peripherally increased bone strength in mice and also increased proliferation of osteoblasts in vitro. Direct peripheral action of leptin on bone seems to be, therefore, rather anabolic 13) . However, the results are contradictory, when leptin is administered centrally. Ducy et al. found that mice with leptin deficiency (ob/ob) and leptin receptor deficiency (db/db) showed increased BMD, and the increase was reversed by intracerebroventricular administration of leptin in ob/ob mice 14) . This indirect action of leptin against bone formation by involving the hypothalamic relay was also documented in consecutive study 15) . A recent animal study has shown that ob/ob mice have low sympathetic activity, suggesting that the central effect of leptin on bone is mediated by the sympathetic nervous system 16) .
The exact role of circulating leptin levels on BMD in human is still contradictory. A previous study has shown that adult patients with congenital leptin deficiency have low BMD values despite their increased fat mass 17) .
Goulding and Taylor have demonstrated that age-adjusted total body BMD values were positively correlated with plasma leptin in postmenopausal femles 18) . More recent clinical trial showed that plasma leptin levels are associated with BMD and the presence of vertebral fractures in postmenopausal women 19) .
There Subjects were also excluded if they were currently exposed to oral contraceptive pills (n = 3). At the entry of the study, no participants were receiving medications known to affect bone metabolism such as calcium, vitamin D, bisphosphonates and anabolic steroids. All except one subject were taking oral hypoglycemic agents.
Current insulin users (n = 11) were not included in the study to achieve the homogeneity of leptin-insulin relationship. After exclusion, 60 females were evaluated in the study.
Biochemical Measurements
Blood was drawn from all patients in the morning following an overnight fast. Plasma samples used for leptin determination were stored at -20℃ and were not thawed until the leptin assay was performed. Serum leptin was measured using a commercial radioimmunoassay The urinary albumin-creatinine ratio (ACR) was measured using a random spot urine sample. Total serum cholesterol was determined by an enzymatic calorimetric test, triglyceride levels by an enzymatic assay without the use of a glycerol blank. High density lipoproteins and low density lipoproteins were measured by an enzymatic selective protection method using a Hitachi Modular Analytics D2400 (Roche, Tokyo, Japan).
BMD and Anthropometric Measurements
At the onset of the study, all subjects underwent physical examinations including height (cm) and weight (kg), and then body mass indexes (kg/m 2 ) were calculated.
BMD at the lumbar vertebrae (L1-4), and femur (femoral neck, trochanter, and femur total) were measured by dual-energy X-ray absorptiometry (DXA) (Lunar Prodigy, General Electric Medical Systems, Milwaukee, Wisconsin, U.S.A.). Body fat mass was measured by a body composition analyzer (Inbody 3.0, Biospace, Seoul, Korea).
Statistical Methods
Statistical analysis was carried out using the SPSS 12.0
for Windows (SPSS, Inc., Chicago, Illinois). BMD values, demographic and biochemical parameters were presented as a mean ± the standard error of the mean (SEM).
Serum leptin concentrations were transformed into a natural logarithm to normalize the skewed distribution.
Pearson's correlation and partial correlation analysis was done to examine the associations between leptin, BMD and confounding factors. Multiple linear regression analysis was performed to look for independent associations between BMD and other variables. A value of P < 0.05 was considered significant.
Results
The anthropometric and biochemical characteristics of 46.5 ± 126.3 Data are presented as mean ± standard deviation. * Serum leptin level is given as median and range due to its skewed distribution. ACR, urine albumin-creatinine ratio; BFM, body fat mass; BMD, bone mineral density; BMI, body mass index; C-peptide, C-peptide level at fasting state; Insulin, insulin level at fasting state. the subjects are shown in Table 1 . The total number of subjects studied was 60. The ages of the patients ranged from 54 to 82 years (65.3 ± 7.4). In accordance with numerous previous studies, natural logarithm transformed serum leptin level was strongly correlated with body fat mass (r = 0.666, P < 0.001), and body mass index (r = 0.542, P < 0.001) (Fig. 1 ). In the unadjusted analysis (Table 2) , age showed a strong negative correlation with BMD, while height, body weight, and body fat mass tended to demonstrate positive correlations. On contrary to previous reports with Previous studies demonstrated positive association between increased insulin dose and increased BMD in diabetic patients 26, 27) . This relationship was observed even in young patients with recent onset type 1 diabetes, leading to the hypothesis that insulin is a cornerstone of bone anabolic factor 28) . Also, Streptozocin-induced diabetic , while some showed negative correlations 19, 20) . Likewise, consensus on the leptin-BMD relationship is not achieved in diabetic patients. In young type 1 diabetic patients, serum leptin showed a negative correlation with total bone mineral content and Z-score 24) . A recent study showed that in obese insulin-resistant premenopausal women, high plasma leptin level no more correlated to higher BMD 37) .
A recent experiment with tail-suspended mice has proposed the idea that a balance between negative and positive leptin effects on bone is dependent on a bimodal This dose-dependent bimodal effect on BMD of leptin is expected to partially explain the diverse leptin-BMD relationship, but cut-off value of serum leptin concentration on opposing two bone phenotypes is not established in
human studies yet. In our study, we hypothesized that serum leptin level might be increased compared to normal controls, thereby contributing to negative trend for bone mineral density. But this was an observational study, and patients with normal glucose tolerance were not enrolled in the study. Moreover, to our knowledge, the definition of leptin resistance is not established in human studies, and the degree of insulin resistance was not included in our study design.
No statistical significance was detected in the relationship between L-spine BMD and leptin in our study, but there is a chance of attenuation of the relationship due to small sample numbers. Moreover, according to Hamrick 39) , in ob/ob mice models, bone mass varied significantly between the axial and appendicular region, and these differences were mainly due to different proportions of trabecular and cortical bone content between the two regions. Lumbar spine BMD was higher due to increased trabecular bone mass, but appendicular BMD was lower because of decrease in cortical bone.
There is a possibility that this discrepant effect of leptin on bone between axial and appendicular region might have induced this preferential leptin effect on femoral BMD in our study.
There were several limitations to our study, the most prominent being the small sample size. Furthermore, the study was cross-sectional, observational study, so no direct relationship between leptin and BMD could be determined. Insulin sensitivity index such as HOMA-IR was not considered in the study design. Biochemical markers of bone formation and bone resorption were not measured.
In conclusion, we postulate that leptin is suggested to 
